Market Overview

UPDATE: Jefferies Raises PT on Abbott Laboratories on Attractive Valuation

Share:
Related ABT
Focus On Abbott Labs Remains On Pending Deals
Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science
Abbott Laboratories: What Should You Do After Q2? (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), and raised the price target from $40.00 to $42.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Abbott Laboratories closed on Tuesday at $36.55.

Latest Ratings for ABT

DateFirmActionFromTo
Jul 2016JefferiesMaintainsBuy
Jun 2016Edward JonesUpgradesHoldBuy
Jun 2016JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!